Press Releases
August 11, 2022
HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates
August 4, 2022
HOOKIPA Pharma to Report Second Quarter 2022 Financial Results on August 11, 2022
July 25, 2022
FDA accepts HOOKIPA’s Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer
June 21, 2022
HOOKIPA Announces Executive Leadership Changes
June 9, 2022
HOOKIPA to Participate in the JMP Securities Life Sciences Conference
June 5, 2022
HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO
June 3, 2022
Preclinical Data on Novel Arenaviral HIV Therapeutic Vaccines Presented at Keystone Symposium
May 26, 2022
HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO
May 16, 2022
HOOKIPA Pharma Reports First Quarter 2022 Financial Results and Recent Highlights
May 9, 2022
HOOKIPA Pharma to Report First Quarter 2022 Financial Results on May 16, 2022
May 3, 2022
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May
May 2, 2022
HOOKIPA announces promotion of Christine D. Baker to Chief Operating Officer
April 20, 2022
HOOKIPA Pharma Appoints Tim Reilly, Ph.D. to its Board of Directors
April 13, 2022
New data show HOOKIPA’s arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigens
April 13, 2022
HOOKIPA to Participate in the Kempen Life Sciences Conference
March 24, 2022
HOOKIPA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Outlook
March 22, 2022
HOOKIPA Announces Promotion of Klaus Orlinger, Ph.D. to Chief Scientific Officer
March 17, 2022
HOOKIPA Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 24, 2022